About This Comparison
Our Editorial Standards
This weight loss provider comparison is independently researched by our editorial team. We compare telehealth services based on publicly available information including pricing, available treatments, service areas, and verified customer reviews.
Independent Research: We do not accept payment for rankings or favorable reviews
Affiliate Disclosure: We may earn commissions from qualifying purchases at no extra cost to you
Regular Updates: Content is reviewed and updated monthly for accuracy
Licensed Providers Only: All listed services employ US-licensed healthcare providers
Not Medical Advice: This comparison is for informational purposes only. We are not healthcare providers. Always consult with a licensed physician before starting any treatment. Read our full medical disclaimer and editorial policy.
Independent ResearchUnbiased provider comparisons
Fact-Checked InformationVerified against official sources
Regularly UpdatedLast updated April 5, 2026
Licensed Providers OnlyAll listed services are US-licensed
Best Topiramate for Weight Loss
Topiramate is an anticonvulsant medication prescribed off-label for weight loss, particularly in combination with phentermine as Qsymia. It reduces appetite and alters taste perception to support weight reduction. Topiramate alone or combined provides effective weight management for obesity.
What Is Topiramate and How Does It Help with Weight Loss?
Topiramate is an anticonvulsant with significant appetite-suppressing effects. It reduces appetite through brain neurotransmitter effects and alters taste perception. Combined with phentermine as Qsymia, it achieves up to 10.6% weight loss.
When combined with phentermine as Qsymia, topiramate has demonstrated up to 10.6% average weight loss after 56 weeks in clinical trials. The combination allows lower doses of each medication while achieving greater results than either alone.
- Anticonvulsant medication with significant appetite-reducing effects
- Used in Qsymia (phentermine/topiramate) for weight management
- Reduces appetite and alters taste perception
- Can be used long-term unlike phentermine alone
Clinical Trial Results: Topiramate Weight Loss Data
The SEQUEL extension study demonstrated maintained weight loss over 2 years: 9.3% and 10.5% loss from baseline at the medium and high doses respectively. This long-term data supports sustained use for chronic weight management.
- EQUIP trial: 14.4% weight loss with highest dose phentermine/topiramate
- CONQUER trial: 12.4% weight loss with highest dose over 56 weeks
- SEQUEL: maintained 10.5% loss over 2 years of treatment
- 67 to 70% achieved 5% or more weight loss across trials
Qsymia: The Phentermine/Topiramate Combination
Qsymia combines phentermine and topiramate in an extended-release capsule, FDA-approved for chronic weight management. By using lower doses of each medication together, Qsymia achieves greater weight loss with fewer side effects than high-dose monotherapy with either.
Available in three dose strengths (3.75/23 mg, 7.5/46 mg, and 15/92 mg), Qsymia allows your provider to titrate treatment based on your response and tolerability. Most patients start at the lowest dose and increase as needed.
With 10 to 14% weight loss in clinical trials, Qsymia results approach some GLP-1 medications while remaining an oral option at a more affordable price point. It is one of the most effective non-injectable weight loss medications available.
- FDA-approved combination for chronic weight management
- Lower doses of each medication reduce individual side effects
- Results rival some GLP-1 medications at a fraction of the cost
- Available in multiple dose strengths for flexible treatment
Topiramate vs GLP-1 Medications for Weight Loss
GLP-1 medications produce higher average weight loss: semaglutide at 14.9% and tirzepatide at up to 20.9%. However, Qsymia at 10 to 14% performs remarkably well compared to injectable options.
As an oral medication, Qsymia appeals to patients who prefer pills over injections. At to per month, it is also more affordable than most GLP-1 medications, particularly for patients without insurance coverage.
- GLP-1 medications produce slightly more weight loss on average
- Qsymia is an oral option that does not require injections
- Qsymia costs to monthly vs to ,400 for GLP-1s
- Some patients combine topiramate with GLP-1 medications
Topiramate Side Effects and Safety
The most distinctive topiramate side effect is paresthesia, a tingling sensation in the hands and feet that occurs in many patients but is generally mild. Dysgeusia (altered taste perception) is another common effect and actually contributes to appetite reduction.
Cognitive side effects including difficulty with word finding, concentration, and memory are reported by some patients, particularly at higher doses. These effects are dose-dependent and reversible when the medication is discontinued or reduced.
Topiramate increases kidney stone risk and patients should stay well hydrated during treatment. It is contraindicated during pregnancy due to risk of cleft lip and palate. Women of childbearing age should use effective contraception while taking topiramate.
- Paresthesia (tingling) is the most distinctive side effect
- Cognitive effects including word-finding difficulty
- Kidney stone risk increases during treatment
- Contraindicated during pregnancy due to birth defect risk
Topiramate Dosing for Weight Management
Qsymia dosing starts at 3.75/23 mg (phentermine/topiramate) taken once daily in the morning for 14 days. After 14 days, the dose increases to 7.5/46 mg. If additional weight loss is needed after 12 weeks, the dose may increase to 11.25/69 mg for 14 days, then to the maximum of 15/92 mg.
Take the capsule in the morning with or without food. Avoid evening dosing as both phentermine and topiramate may affect sleep. Swallow whole - do not open, crush, or chew the extended-release capsules.
If you do not achieve 3% weight loss after 12 weeks on the maximum dose, your provider may recommend discontinuing Qsymia, as this predicts poor long-term response. Gradual tapering is recommended to reduce seizure risk when stopping topiramate.
- As Qsymia: starts at 3.75/23 mg daily
- Can increase to 7.5/46 mg or 15/92 mg based on response
- Extended-release capsule taken once daily in the morning
- Gradual titration reduces cognitive and tingling side effects
Who Qualifies for Topiramate Treatment Online?
Qsymia is indicated for adults with BMI of 30 or higher, or 27 or higher with at least one weight-related comorbidity. Telehealth providers assess eligibility through complete health evaluations.
Topiramate is strictly contraindicated during pregnancy due to risk of birth defects. Women of childbearing age must use reliable contraception and may need pregnancy testing before starting and periodically during treatment.
- BMI of 30+ or 27+ with weight-related conditions
- Not appropriate during pregnancy or while planning pregnancy
- Kidney stone history requires careful evaluation
- Glaucoma patients should not take topiramate
Topiramate Cost and Insurance Options
Generic topiramate prescribed standalone is very affordable at to per month. Qsymia (the FDA-approved combination) costs approximately to monthly. Both are significantly cheaper than GLP-1 injectable medications.
Some insurance plans cover Qsymia with prior authorization for documented obesity. Generic topiramate is covered by most plans when prescribed for any approved indication.
For patients seeking effective weight loss at an affordable price without injections, Qsymia offers excellent value with clinical results approaching injectable GLP-1 medications.
- Generic topiramate costs to per month
- Qsymia costs to per month
- Some insurance plans cover Qsymia with prior authorization
- One of the most cost-effective weight loss options available
Long-Term Use and Sustained Results
When discontinuing topiramate, gradual tapering over at least one week is recommended to reduce seizure risk. Do not stop the medication abruptly. Your provider will create a safe tapering schedule.
Use the treatment period to establish sustainable eating patterns and physical activity habits. While Qsymia provides effective appetite control, building these habits supports your results whether you continue treatment or eventually taper.
- SEQUEL trial showed maintained weight loss over 2 years
- Topiramate can be used long-term unlike phentermine alone
- Gradual tapering needed when discontinuing to prevent seizures
- Building sustainable habits during treatment supports lasting results
Choosing the Right Provider
Select a telehealth provider that thoroughly screens for contraindications including pregnancy risk, glaucoma, kidney stone history, and cognitive concerns. Proper screening is essential for safe topiramate use.
The provider should monitor for cognitive side effects and have clear protocols for dose reduction if these become problematic. Regular follow-ups should assess both weight loss progress and medication tolerability.
Choose a provider offering multiple weight loss medication options so you can transition to alternative treatments if topiramate does not produce adequate results or if side effects become problematic.
- Ensure provider screens for pregnancy risk and kidney stone history
- Look for proper monitoring of cognitive side effects
- Ask about the full dose range and titration approach
- Choose a program that offers multiple medication options
Frequently Asked Questions
How effective is topiramate for weight loss?
Topiramate produces 5 to 10 percent weight loss on average over 6 to 12 months. When combined with phentermine as Qsymia, average weight loss increases to 10 to 15 percent. Individual results vary based on dose, adherence, and lifestyle changes.
Sources & References
Our comparisons are informed by official sources and regulatory guidelines. We encourage readers to verify information with authoritative sources.
- Topiramate is an anticonvulsant with significant appetite-suppressing effects. It reduces appetite through brain neurotransmitter effects and alters taste perception
- Combined with phentermine as Qsymia, it achieves up to 10.6% weight loss
- Unlike phentermine limited to short-term use, topiramate can be prescribed longer. Phentermine and topiramate ER together have been reviewed for their role in complications-centric obesity management
- The EQUIP trial evaluated 1,267 obese patients over 56 weeks. The maximum dose phentermine/topiramate (15/92 mg) produced 14.4% weight loss, with 67% achieving at least 5% and 47% achieving at least 10% loss
- The CONQUER trial in 2,487 patients showed 12.4% weight loss at the maximum dose, with 70% achieving 5% or more and 48% achieving 10% or more over 56 weeks
- The SEQUEL extension study demonstrated maintained weight loss over 2 years: 9.3% and 10.5% loss from baseline at the medium and high doses respectively
- GLP-1 medications produce higher average weight loss: semaglutide at 14.9%
- tirzepatide at up to 20.9%
- Your provider can help determine the best approach. Phentermine/topiramate for obesity treatment has been independently reviewed for clinical guidance
- Additional contraindications include glaucoma and hyperthyroidism. The clinical utility of Qsymia for obesity treatment has been reviewed in dedicated clinical assessments
Editorial Note: Researched and edited by our editorial team. AI tools assist with initial research and drafting; all content is fact-checked and edited by humans before publication. Learn more about our editorial standards